AstraZeneca PLC filed a Form 6-K on 2 November 2026 notifying the admission of 11,948 further ordinary shares to trading on the London Stock Exchange Main Market, issued under the company's employee share schemes between 1 October 2026 and 31 October 2026.

Key Highlights

  • Shares admitted: 11,948 ordinary shares of $0.25 each were issued and admitted to trading on the London Stock Exchange Main Market.
  • Total shares in issue: Following this admission, the total number of AstraZeneca ordinary shares in issue is 1,551,065,237, according to the filing.
  • Issuance period: The shares were issued between 1 October 2026 and 31 October 2026 under employee share schemes.
  • Block admission: The shares were admitted under a block admission dated 29 January 2021.
  • Fungibility: The filing states the new shares are "fully fungible with existing Ordinary Shares."
  • ISIN: The ordinary shares carry ISIN GB0009895292.

AstraZeneca Reports October 2026 Employee Share Scheme Admission Details

AstraZeneca PLC (LSE/STO/NYSE:AZN) submitted a Form 6-K to the U.S. Securities and Exchange Commission on 2 November 2026, disclosing the admission of further securities to trading on the London Stock Exchange Main Market. According to the filing, the notification was made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

The filing states that 11,948 ordinary shares of $0.25 each, identified by ISIN GB0009895292, were issued under the company's employee share schemes during the period from 1 October 2026 to 31 October 2026. These shares were admitted to trading on the London Stock Exchange Main Market under AstraZeneca's existing block admission of shares dated 29 January 2021. The filing confirms that no prospectus or supplementary prospectus was applicable to this admission.

Following the admission of these shares, the total number of AstraZeneca ordinary shares in issue stands at 1,551,065,237, as reported in the filing. The newly issued shares are described as "fully fungible with existing Ordinary Shares." The LEI recorded for AstraZeneca PLC in the filing is PY6ZZQWO2IZFZC3IOL08. The filing was signed by Matthew Bowden, Company Secretary of AstraZeneca PLC, on 2 November 2026.

What Was Disclosed

AstraZeneca PLC disclosed the admission of 11,948 ordinary shares to the London Stock Exchange Main Market, issued under employee share schemes between 1 October and 31 October 2026, bringing total shares in issue to 1,551,065,237.